Centaurus Financial - we invest in your success
CuraDebit Free Debt Analysis
  Home > Fortune 500 Companies > Baxter Intl

Baxter Intl



Baxter Intl is a publicly traded company having a good stock performance result. Baxter Intl is a fortune 500 stock listed company trading under BAX.




 


Baxter International Inc.is a global healthcare company that, through its subsidiaries assists healthcare professionals and their patients with treatment of complex medical conditions including hemophilia, immune disorders, kidney disease, cancer, trauma and other conditions. With 2005 sales of 9.8 billion, and approximately 47,000 employees, Baxter applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives. 


For the third quarter of 2005, the company expects organic sales growth of 2 to 4 percent, and earnings per diluted share from continuing operations of 0.45 to 0.47 billon dollars. For full-year 2005, Baxter expects organic sales growth of 2 to 4 percent and adjusted earnings per diluted share from continuing operations of 1.86 dollars to 1.90 dollars. BAX also expects cash flow from continuing operations to exceed 1.6 billion dollars, and to generate free cash flow of at least 1.0 billion dollars in 2005.  


The company's guidance above excludes the 0.02 dollars per diluted share net benefit from the second-quarter charge and restructuring adjustment, future pre-tax charges expected to total 40 to 50 million dollars related to the rationalization of its hemo dialysis instrument manufacturing capacity, and the cost to repatriate foreign earnings under the American Jobs Creation Act of 2004. Including the 0.02 dollars per diluted share net benefit of the second-quarter items, Baxter's full-year earnings guidance under Generally Accepted Accounting Principles (GAAP) is expected to be 1.88 dollars to 1.92 dollars per diluted share. 


Worldwide sales in the second quarter totaled 2.6 billion dollars; domestic sales increased 6 percent to 1.2 billion dollars, while international sales grew 11 percent to 1.4 billion dollars. Sales of Baxter's recombinant products grew 24 percent to 397 million dollars, including 148 million dollars in sales for the treatment of hemophilia A.


The company is committed to improve their business processes and product quality, continue to execute upon their long-term business strategies, and leverage the value inherent within their business portfolio. Baxter’s history is rich with medical firsts, from the first commercially manufactured intravenous solutions to the first portable kidney dialysis machine, plus many more. Baxter continually pursues breakthrough technologies through research facilities around the world, and their investments reflect that commitments.




Back to Fortune 500 Companies

 
 
Infinit-i